Clofibrate Side Effects
Medically reviewed by Drugs.com. Last updated on Nov 2, 2024.
Applies to clofibrate: oral capsule.
Important warnings
This medicine can cause some serious health issues
Follow any diet or exercise plan outlined by your doctor.
Diet and exercise are very important factors in controlling cholesterol.
Call your doctor immediately if you experience chest pain, shortness of breath, an irregular heartbeat, severe stomach pain with nausea and vomiting, fever and chills, a sore throat, a flulike feeling, blood in your urine, a decrease in urination, muscle cramps, muscle pain, muscle weakness, painful joints, swelling in your ankles or legs, or sudden weight gain.
These could be early signs of serious side effects.
If you experience any of the following serious side effects, stop taking clofibrate and seek emergency medical attention:
-
an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives);
-
chest pain or an irregular heart beat;
-
severe stomach pain with nausea and vomiting;
-
fever and chills, a sore throat, or a flu-like feeling;
-
blood in your urine or a decrease in urination;
-
swelling of your ankles or legs;
-
muscle cramps, muscle weakness, muscle aches, or muscle pain;
-
joint pain; or
-
sudden weight gain.
Other, less serious side effects may be more likely to occur. Continue to take clofibrate and talk to your doctor if you experience
-
bloating or flatulence;
-
nausea, vomiting, or diarrhea;
-
headache;
-
dizziness or drowsiness; or
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.
For healthcare professionals
Applies to clofibrate: oral capsule.
General adverse events
In general, the most common adverse effects due to clofibrate therapy are gastrointestinal in nature (especially nausea) and may subside over time or with a decreased dosage.[Ref]
Gastrointestinal
Gastrointestinal reactions may include nausea, vomiting, diarrhea, gastritis, weight loss or gain, and gallstones (during prolonged therapy).[Ref]
Cholelithiasis and cholecystitis (sometimes requiring surgery or resulting in pancreatitis) occur more frequently in patients receiving clofibrate than in patients receiving placebo.[Ref]
Musculoskeletal
Musculoskeletal effects (myopathy) typically occur as a "flu-like" syndrome (myalgia, cramps, muscle weakness, and arthralgia). Rhabdomyolysis with an accompanying increase in creatinine kinase and creatinine phosphokinase (CPK) has been reported in patients with renal disease.[Ref]
Patients diagnosed with rhabdomyolysis are usually asymptomatic clinically several days after discontinuing clofibrate, but the muscle enzymes may remain elevated for a more prolonged period. Severe renal disease may increase the risk of myopathies, perhaps because of accumulation of the active metabolite clofibric acid.[Ref]
Metabolic
Electrolyte disturbances like hyperkalemia have been reported in patients with renal insufficiency who receive clofibrate.[Ref]
Nervous system
Central nervous system depressant effects may include fatigue, weakness, drowsiness, and/or dizziness. Headache has also been reported.[Ref]
Hematologic
Hematologic adverse effects may include leukopenia, anemia, eosinophilia, agranulocytosis, and potentiation of anticoagulant effects. Because of these effects, some clinicians recommend periodic monitoring of blood counts.[Ref]
Cardiovascular
Cardiovascular complications may include various arrhythmias and altered angina pectoris. Swelling and phlebitis have occurred at xanthomata sites.[Ref]
Renal
Renal dysfunction (including dysuria, hematuria, proteinuria, and decreased urine output) has been reported. Acute renal failure and interstitial nephritis have also been reported.[Ref]
Genitourinary
Decreased libido (primarily in men) and impotence have been reported.[Ref]
Hepatic
Hepatic disorders may include elevated liver enzymes and/or hepatomegaly. (Liver biopsy, when performed in this setting, is usually normal.) Clofibrate should be used cautiously for patients with a history of jaundice or liver disease.[Ref]
Dermatologic
Dermatologic reactions which occur in about 2% of patients may include urticaria, rash, dry skin, and alopecia. Erythema multiforme, toxic epidermal necrolysis, and Stevens-Johnson syndrome have occurred rarely.[Ref]
Hypersensitivity
One case of a hypersensitivity reaction occurring as eosinophilic pneumonia has been reported.[Ref]
Other
Fever, which occurred on rechallenge with clofibrate, has been reported in one case.[Ref]
Oncologic
Oncologic effects of tumor growth in rodents have been associated with many lipid-lowering drugs. Clofibrate has been associated with liver, pancreatic and testicular tumors in rats. Long-term clinical trials are needed to define the risk of cancer in humans.[Ref]
References
1. (2001) "Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories
2. Faergeman O (1973) "Effects and side-effects of treatment of hypercholesterolemia with cholestyramine and neomycin." Acta Med Scand, 194, p. 165-7
3. Cayen MN (1985) "Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man." Pharmacol Ther, 29, p. 157-204
4. Pokroy N, Ress S, Gregory MC (1977) "Clofibrate-induced complications in renal disease: a case report." S Afr Med J, 52, p. 806-8
5. Abourizk N, Khalil BA, Bahuth N, Afifi AK (1979) "Clofibrate-induced muscular syndrome. Report of a case with clinical, electromyographic and pathologic observations." J Neurol Sci, 42, p. 1-9
6. Rush P, Baron M, Kapusta M (1986) "Clofibrate myopathy: a case report and a review of the literature." Semin Arthritis Rheum, 15, p. 226-9
7. Shepherd J (1995) "Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety." Eur Heart J, 16, p. 5-13
8. Duell PB, Connor WE, Illingworth DR (1998) "Rhabdomyolysis after taking atorvastatin with gemfibrozil." Am J Cardiol, 81, p. 368-9
9. Cumming A (1980) "Acute renal failure and interstitial nephritis after clofibrate treatment." Br Med J, 281, p. 1529-30
10. Murata Y, Tani M, Amano M (1988) "Erythema multiforme due to clofibrate ." J Am Acad Dermatol, 18, p. 381-2
11. Wong SS (1994) "Stevens-Johnson syndrome induced by clofibrate." Acta Derm Venereol, 74, p. 475
12. Hendrickson RM, Simpson F (1982) "Clofibrate and eosinophilic pneumonia ." JAMA, 247, p. 3082
13. Beckner RR, Canada AT, Ockene IS (1979) "Fever due to clofibrate ." N Engl J Med, 301, p. 1345-6
More about clofibrate
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: fibric acid derivatives
Patient resources
Related treatment guides
Further information
Clofibrate side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.